Radar›Companies›Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 5
United States pharmaceutical preparations industry landscape illustrating listed-company operations, infrastructure and market activity
Prism Finance USA · comparison snapshot

Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 5

A five-company pharmaceutical preparations cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 31 August 2026Not investment adviceRanked by Prism readiness
Readiness leaderArrowhead Pharmaceuticals · 54
Strongest available pathMirum Pharmaceuticals · +392.2%
Widest latest marginRigel · 124.7%
Companies compared5 · U.S.-listed
01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1ARWR · Nasdaq

Arrowhead Pharmaceuticals

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1989CAMDEN$11.61B market cap
View full Companies Radar profile
54Moderate
Snapshot price$82.39as of page date
Monthly-close return+32.0%five-year window
FY2025 revenue$0.83BARROWHEAD PHARMACEUTICALS, INC.
Net margin-0.2%FY2025
P/E snapshot-16.9xone ratio, not a verdict
Prism attention9.3%share across these five
Filing track recordRevenue, USD billions
+499.8%
$0$0.3B$0.6B$0.8BFY2021: $0.138BFY2022: $0.243BFY2023: $0.241BFY2024: $0.004BFY2025: $0.829B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 56.5%
52-week position82% through range
$22.73$95.49
News mentions1.8K
Community mentions0partial coverage
U.S.-scope patents1203
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal61/100
Management stability90/100
Market position13/100
Capital-event signal88/100
Innovation pulse8/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 1 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 1 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2FBIO · Nasdaq

Fortress Biotech

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2006DOVER$91.2M market cap
View full Companies Radar profile
54Moderate
Snapshot price$2.73as of page date
Monthly-close return-94.3%five-year window
FY2025 revenue$0.06BFortress Biotech, Inc.
Net margin11.1%FY2025
P/E snapshot1.0xone ratio, not a verdict
Prism attention5.7%share across these five
Filing track recordRevenue, USD billions
-3.0%
$0$0.0B$0.0B$0.1BFY2021: $0.063BFY2022: $0.071BFY2023: $0.060BFY2024: $0.055BFY2025: $0.061B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -0.8%
52-week position23% through range
$2.18$4.53
News mentions1.1K
Community mentions14partial coverage
U.S.-scope patents4
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal71/100
Management stability90/100
Market position4/100
Capital-event signal70/100
Innovation pulse15/100
Management signal

No leadership-churn flag in the model; 2 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 2 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3MIRM · Nasdaq

Mirum Pharmaceuticals

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2018Menlo Park, California$5.98B market cap
View full Companies Radar profile
54Moderate
Snapshot price$98.05as of page date
Monthly-close return+392.2%five-year window
FY2025 revenue$0.52BMirum Pharmaceuticals, Inc.
Net margin-4.5%FY2025
P/E snapshot-282.8xone ratio, not a verdict
Prism attention5.4%share across these five
Filing track recordRevenue, USD billions
+576.5%
$0$0.2B$0.3B$0.5BFY2022: $0.077BFY2023: $0.186BFY2024: $0.337BFY2025: $0.521B2022202320242025
FY2022–FY2025 · 4 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 89.1%
52-week position52% through range
$63.23$130.0
News mentions1.0K
Community mentions11partial coverage
U.S.-scope patents135
Prism Insights

What sits behind the readiness signal

Observed risk 4/100higher means more observed risk
Earnings signal72/100
Management stability90/100
Market position18/100
Capital-event signal67/100
Innovation pulse12/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 9 M&A involvements, 4 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 11 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4ACAD · Nasdaq

Acadia

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1993San Diego, California$4.95B market cap
View full Companies Radar profile
53Moderate
Snapshot price$28.91as of page date
Monthly-close return+74.1%five-year window
FY2025 revenue$1.07BACADIA PHARMACEUTICALS INC
Net margin36.5%FY2025
P/E snapshot13.0xone ratio, not a verdict
Prism attention67.9%share across these five
Filing track recordRevenue, USD billions
+121.3%
$0$0.4B$0.7B$1.1BFY2021: $0.484BFY2022: $0.517BFY2023: $0.726BFY2024: $0.958BFY2025: $1.072B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 22.0%
52-week position82% through range
$19.69$30.96
News mentions13.0K
Community mentions861partial coverage
U.S.-scope patents645
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal70/100
Management stability90/100
Market position12/100
Capital-event signal49/100
Innovation pulse24/100
Management signal

No leadership-churn flag in the model; 5 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 5 M&A involvements, 1 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 1 lifetime product-launch events, 0 in the latest 360 days, and 5 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5RIGL · Nasdaq

Rigel

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1996San Francisco, California$854.4M market cap
View full Companies Radar profile
53Moderate
Snapshot price$46.18as of page date
Monthly-close return+27.2%five-year window
FY2025 revenue$0.29BRIGEL PHARMACEUTICALS INC
Net margin124.7%FY2025
P/E snapshot2.7xone ratio, not a verdict
Prism attention11.7%share across these five
Filing track recordRevenue, USD billions
+97.2%
$0$0.1B$0.2B$0.3BFY2021: $0.149BFY2022: $0.120BFY2023: $0.117BFY2024: $0.179BFY2025: $0.294B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 18.5%
52-week position78% through range
$24.95$52.24
News mentions2.2K
Community mentions0partial coverage
U.S.-scope patents2431
Prism Insights

What sits behind the readiness signal

Observed risk 4/100higher means more observed risk
Earnings signal74/100
Management stability90/100
Market position3/100
Capital-event signal75/100
Innovation pulse10/100
Management signal

No leadership-churn flag in the model; 2 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 0 asset-acquisition events and 6 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Mirum Pharmaceuticals
+392.2%
Acadia
+74.1%
Arrowhead Pharmaceuticals
+32.0%
Rigel
+27.2%
Fortress Biotech
-94.3%

Latest revenue

USD billions, official filing scope shown on each company card.

Acadia
$1.07B
Arrowhead Pharmaceuticals
$0.83B
Mirum Pharmaceuticals
$0.52B
Rigel
$0.29B
Fortress Biotech
$0.06B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Rigel
124.7%
Acadia
36.5%
Fortress Biotech
11.1%
Arrowhead Pharmaceuticals
-0.2%
Mirum Pharmaceuticals
-4.5%

Prism news attention

Normalized share across these five names; attention is not quality.

Acadia
67.9%
Rigel
11.7%
Arrowhead Pharmaceuticals
9.3%
Fortress Biotech
5.7%
Mirum Pharmaceuticals
5.4%
03 · Prism readout

What the signals say—and what they do not

The headline share is normalized pharmaceutical preparations news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Acadia leads the conversation

It holds 67.9% of measured pharmaceutical preparations news attention and also carries the basket's largest revenue base at $1.07B.

Price path

Mirum Pharmaceuticals leads the available price paths

Its monthly-close return is +392.2% for the five-year window. At the other end, Fortress Biotech is -94.3% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Rigel has the widest latest margin

Its FY2025 net margin is 124.7%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Mirum Pharmaceuticals shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -282.8x while its five-year window price return is +392.2%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · ARWR

Arrowhead Pharmaceuticals

1,771available Prism news records

Prism top themes

Price action & investor response
105
Legal, arbitration & regulatory
47
Capital allocation & transactions
40
Earnings & financial performance
35
Leadership & governance
15

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+99.0%575 latest 12m vs 289 prior 12m
2024-01: 16 mentions2024-02: 15 mentions2024-03: 14 mentions2024-04: 27 mentions2024-05: 27 mentions2024-06: 19 mentions2024-07: 6 mentions2024-08: 22 mentions2024-09: 17 mentions2024-10: 13 mentions2024-11: 40 mentions2024-12: 26 mentions2025-01: 32 mentions2025-02: 44 mentions2025-03: 29 mentions2025-04: 23 mentions2025-05: 24 mentions2025-06: 13 mentions2025-07: 27 mentions2025-08: 30 mentions2025-09: 63 mentions2025-10: 40 mentions2025-11: 55 mentions2025-12: 16 mentions2026-01: 104 mentions2026-02: 75 mentions2026-03: 30 mentions2026-04: 43 mentions2026-05: 83 mentions2026-06: 9 mentions2024-012026-06

Machine-classified coverage tone

93.8% positive-0.9 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

gene therapy rare diseases 68stock performance 40stock price 33orphan drug pricing 29rare disease treatment 28startup valuation 25stem cell banking 23rare disease clinical trials 22

Keyword tag occurrences in available Prism news records.

Coverage: 2010-02-02–2026-06-13 · trend and themes shown through 2026-06
Areas of research · FBIO

Fortress Biotech

1,085available Prism news records

Prism top themes

Price action & investor response
40
Legal, arbitration & regulatory
35
Capital allocation & transactions
21
Earnings & financial performance
12
Leadership & governance
7

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-17.8%139 latest 12m vs 169 prior 12m
2024-01: 21 mentions2024-02: 6 mentions2024-03: 40 mentions2024-04: 15 mentions2024-05: 27 mentions2024-06: 17 mentions2024-07: 25 mentions2024-08: 13 mentions2024-09: 13 mentions2024-10: 9 mentions2024-11: 12 mentions2024-12: 5 mentions2025-01: 16 mentions2025-02: 15 mentions2025-03: 28 mentions2025-04: 7 mentions2025-05: 14 mentions2025-06: 12 mentions2025-07: 7 mentions2025-08: 19 mentions2025-09: 4 mentions2025-10: 26 mentions2025-11: 12 mentions2025-12: 10 mentions2026-01: 17 mentions2026-02: 9 mentions2026-03: 13 mentions2026-04: 8 mentions2026-05: 11 mentions2026-06: 3 mentions2024-012026-06

Machine-classified coverage tone

98.6% positive-0.2 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

checkpoint inhibitors 15stock performance 14bla approval 10rare disease treatment 10gene therapy rare diseases 9stock indices 8cancer biomarkers 8orphan drug pricing 8

Keyword tag occurrences in available Prism news records.

Coverage: 2010-05-12–2026-06-29 · trend and themes shown through 2026-06
Areas of research · MIRM

Mirum Pharmaceuticals

1,035available Prism news records

Prism top themes

Price action & investor response
95
Capital allocation & transactions
49
Earnings & financial performance
38
Leadership & governance
27
Legal, arbitration & regulatory
22

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+111.3%300 latest 12m vs 142 prior 12m
2024-01: 12 mentions2024-02: 13 mentions2024-03: 16 mentions2024-04: 6 mentions2024-05: 16 mentions2024-06: 23 mentions2024-07: 7 mentions2024-08: 9 mentions2024-09: 1 mentions2024-10: 10 mentions2024-11: 12 mentions2024-12: 5 mentions2025-01: 16 mentions2025-02: 41 mentions2025-03: 12 mentions2025-04: 8 mentions2025-05: 18 mentions2025-06: 3 mentions2025-07: 4 mentions2025-08: 18 mentions2025-09: 15 mentions2025-10: 6 mentions2025-11: 16 mentions2025-12: 28 mentions2026-01: 40 mentions2026-02: 51 mentions2026-03: 22 mentions2026-04: 30 mentions2026-05: 60 mentions2026-06: 10 mentions2024-012026-06

Machine-classified coverage tone

88.4% positive-10.1 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock price 49share price 40company valuation 32rare disease treatment 22rare disease clinical trials 18stock performance 18startup valuation 15market reaction 13

Keyword tag occurrences in available Prism news records.

Coverage: 2015-05-06–2026-06-19 · trend and themes shown through 2026-06
Areas of research · ACAD

Acadia

12,999available Prism news records

Prism top themes

Price action & investor response
169
Earnings & financial performance
106
Capital allocation & transactions
90
Leadership & governance
78
Legal, arbitration & regulatory
70

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-28.4%1,482 latest 12m vs 2,070 prior 12m
2024-02: 106 mentions2024-03: 148 mentions2024-04: 125 mentions2024-05: 141 mentions2024-06: 91 mentions2024-07: 89 mentions2024-08: 110 mentions2024-09: 196 mentions2024-10: 221 mentions2024-11: 229 mentions2024-12: 138 mentions2025-01: 159 mentions2025-02: 405 mentions2025-03: 127 mentions2025-04: 128 mentions2025-05: 136 mentions2025-06: 101 mentions2025-07: 120 mentions2025-08: 194 mentions2025-09: 175 mentions2025-10: 133 mentions2025-11: 124 mentions2025-12: 116 mentions2026-01: 110 mentions2026-02: 160 mentions2026-03: 126 mentions2026-04: 182 mentions2026-05: 135 mentions2026-06: 25 mentions2026-07: 2 mentions2024-022026-07

Machine-classified coverage tone

75.1% positive+2.0 pp vs preceding four quarters
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

national park 84stock performance 58national park adventures 55wilderness conservation 43hiking trails 41orphan drug pricing 37stock price 36gene therapy rare diseases 32

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-06–2026-07-16 · trend and themes shown through 2026-07
Areas of research · RIGL

Rigel

2,242available Prism news records

Prism top themes

Price action & investor response
93
Capital allocation & transactions
46
Earnings & financial performance
20
Leadership & governance
19
Legal, arbitration & regulatory
19

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-29.8%340 latest 12m vs 484 prior 12m
2024-01: 20 mentions2024-02: 23 mentions2024-03: 19 mentions2024-04: 19 mentions2024-05: 13 mentions2024-06: 12 mentions2024-07: 16 mentions2024-08: 11 mentions2024-09: 11 mentions2024-10: 8 mentions2024-11: 18 mentions2024-12: 12 mentions2025-01: 35 mentions2025-02: 271 mentions2025-03: 35 mentions2025-04: 6 mentions2025-05: 18 mentions2025-06: 43 mentions2025-07: 22 mentions2025-08: 17 mentions2025-09: 30 mentions2025-10: 23 mentions2025-11: 27 mentions2025-12: 25 mentions2026-01: 28 mentions2026-02: 40 mentions2026-03: 26 mentions2026-04: 44 mentions2026-05: 52 mentions2026-06: 6 mentions2024-012026-06

Machine-classified coverage tone

91.8% positive+0.4 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock price 24angiogenesis inhibitors 19stock performance 13astrometry 11orphan drug pricing 11company valuation 10phase iii trial 9startup valuation 8

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-20–2026-06-05 · trend and themes shown through 2026-06
05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

ACAD

Acadia

861 mentions
Stock and valuation
105
Products, pricing and logistics
24
Workplace and hiring
7

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 861 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

ARWR

Arrowhead Pharmaceuticals

through 2026-04-20
Earnings releases 20Listing / IPO 2Business contracts 1Company announcements 1Leadership changes 1
  1. Company announcements

    Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR ) today announced that it will host a webcast and conference call on May 7, 2026, at 4:30 p.m. ET to discuss its financial results for the fiscal 2026 second quarter ended March 31, 2026.

  2. Earnings releases

    Three months Ended December 31, 2025, Revenue $ 264,033, Operating income (loss) $ 40,809, Net income (loss) $ 28,242, Net income per share attributable to Arrowhead Pharmaceuticals, Inc. diluted $ 0.22.

  3. Business contracts

    Upon closing of the agreement in February 2025, Arrowhead received a $500 million upfront payment and $325 million through the purchase by Sarepta of Arrowhead common stock priced at $27.25 per share.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

FBIO

Fortress Biotech

through 2026-03-30
Earnings releases 15Regulatory 6Asset acquisitions 2Leadership changes 2
  1. Asset acquisitions

    we sold our former subsidiary Checkpoint Therapeutics to Sun Pharma.

  2. Earnings releases

    Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fortress Biotech $57.67 million 2.00 -$46.00 million ($0.18) -20.67

  3. Leadership changes

    Fortress Biotech, Inc., a biopharma company, has appointed David Jin as chief financial officer, effective Aug. 16. He will also continue to serve as head of corporate development.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

MIRM

Mirum Pharmaceuticals

through 2026-04-29
Company announcements 31Earnings releases 27M&A 5Regulatory 5Asset acquisitions 4
  1. Earnings releases

    Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM ), a leading rare disease company, today announced that it will report first quarter 2026 financial results on May 6, 2026.

  2. Company announcements

    Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM ), a leading rare disease company, today announced that on April 10, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 13,700 shares of common stock and 18,200 restricted stock units (“RSUs”) to 12 new employees under Mirum’s 2020 Inducement Plan.

  3. Regulatory

    Health Canada approves LIVMARLI for patients with PFIC and Alagille syndrome.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

ACAD

Acadia

through 2026-03-03
Company announcements 33Leadership changes 29Earnings releases 19Listing / IPO 9Regulatory 4
  1. Leadership changes

    Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Jonathan M. Poole to its Board of Directors, effective March 3, 2026.

  2. Earnings releases

    GAAP total revenues were $284 million for the fourth quarter of 2025.

  3. Company announcements

    Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on September 4, 2025, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 161,676 shares of common stock and 49,363 restricted stock units (“RSUs”) to eighteen new employees under Acadia’s 2024 Inducement Plan.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

RIGL

Rigel

through 2026-04-28
Earnings releases 31Listing / IPO 9Leadership changes 3Regulatory 3Company announcements 2
  1. Earnings releases

    Rigel Pharmaceuticals, Inc. today announced that it will report its first quarter 2026 financial results after market close on Tuesday, May 5, 2026.

  2. Leadership changes

    Rigel Pharmaceuticals appointed Michael P. Miller to the board of directors.

  3. Regulatory

    Rigel Pharmaceuticals Inc.’s ahead-of-deadline approval from the U.S. FDA of Rezlidhia (olutasidenib) twice-daily capsules for adults with relapsed/refractory (r/r) acute myeloid leukemia (AML) came as a surprise to the company

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Pharmaceutical Preparations Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary pharmaceutical preparations news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

pharmaceutical industry

36 sources100.0% extraction confidence
2011 extracted base$66.70B
2016 extracted forecast$42.00B–$70.00B
Implied source CAGR9.5%
Macro and micro trends driving the industry's futureR&D expenditure and leading therapeutic areasGrowth opportunities

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, India, China, U.S.. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Pharmaceutical Preparations news pulse

55,282available Prism news records
Latest 12m volume+3.4%24052 vs 23272 records
Positive classified tone65.3%+6.0 pp vs prior four quarters
2024-01: 2,385 mentions2024-02: 1,423 mentions2024-03: 1,374 mentions2024-04: 1,289 mentions2024-05: 1,487 mentions2024-06: 1,819 mentions2024-07: 1,355 mentions2024-08: 1,609 mentions2024-09: 1,720 mentions2024-10: 1,625 mentions2024-11: 1,853 mentions2024-12: 1,522 mentions2025-01: 2,799 mentions2025-02: 2,971 mentions2025-03: 2,174 mentions2025-04: 2,142 mentions2025-05: 1,683 mentions2025-06: 1,142 mentions2025-07: 1,921 mentions2025-08: 3,922 mentions2025-09: 2,081 mentions2025-10: 1,648 mentions2025-11: 1,720 mentions2025-12: 1,496 mentions2026-01: 1,701 mentions2026-02: 3,364 mentions2026-03: 1,972 mentions2026-04: 2,867 mentions2026-05: 218 mentions2024-012026-05
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Available U.S.-primary Prism records matching pharmaceutical, preparation. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

drug pricing and reimbursement strategies
6,223
snowstorm and blizzard alerts
6,121
pharmaceutical marketing and sales strategies
6,014
winter weather preparedness
5,925
generic drug development and market trends
3,700
healthcare economics and market access
3,498

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

ice storm preparation 6,522snowstorm advisory 5,649cold weather readiness 5,010heavy snow warning 4,972winter storm alert 4,355snow accumulation alert 4,114life-threatening weather 2,915severe weather warning 2,905

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

Macro and micro trends driving the industry's future

36 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card
Opportunity · demand

drug pricing and reimbursement strategies

6,223 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata
Opportunity · innovation

Innovation and product activity

5,689 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule
Caution · market restraint

regulatory changes

5,709 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata
Caution · news pulse

Coverage growth can reverse

+3.4% news volume

The latest 12 months contain 24,052 matched records versus 23,272 in the previous window.

Available Prism coverage through 2026-05-05
Caution · sentiment

Classified tone is not demand

65.3% positive · +6.0pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →
08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2834 (Pharmaceutical Preparations), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 21–28. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

  • Official annual filingsFY revenue history and latest profitability
  • U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
  • Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
  • Prism market-growth extractionDated third-party Pharmaceutical Preparations Industry in USA market benchmark with source-count, geography and confidence context
Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 31 August 2026.
09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions
Comparisons
Anomalies

Acadia has the widest attention-readiness rank gap

It ranks #1 by measured news attention (67.9%) and #4 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Acadia in Companies Radar

Arrowhead Pharmaceuticals shows a price-operating divergence to inspect

Its displayed filing-revenue change is +499.8% while its available monthly-close return is +32.0%. This is the basket's largest numerical spread; the measures use different units and windows and are not directly equivalent.

Open Arrowhead Pharmaceuticals in Companies Radar
Explanations

Attention measures coverage volume, not quality

Acadia's 67.9% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Acadia in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Arrowhead Pharmaceuticals's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 54/100 score.

Open Arrowhead Pharmaceuticals in Companies Radar
Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.
Coming soon